Or Gozani

20PUBLICATIONS
105CO-AUTHORS
Predictive and prognostic markersEpigenetics (incl. genome methylation and epigenomics)Molecular targetsGene and molecular therapySeparation technologies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Nov 26, 2025
NSD2 targeting reverses plasticity and drug resistance in prostate cancer.

Jia J Li, Alessandro Vasciaveo, Dimitris Karagiannis

|Sep 15, 2025
SETD2 suppresses tumorigenesis in a KRASG12C-driven lung cancer model, and its catalytic activity is regulated by histone acetylation.

Ricardo J Mack, Natasha M Flores, Geoffrey C Fox

|Aug 06, 2025
NSD2 inhibitors rewire chromatin to treat lung and pancreatic cancers.

Jinho Jeong, Simone Hausmann, Hanyang Dong

|Jun 04, 2025
SETD2 suppresses tumorigenesis in a KRASG12C-driven lung cancer model and its catalytic activity is regulated by histone acetylation.

Ricardo J Mack, Natasha M Flores, Geoffrey C Fox

|Jul 24, 2024
SMYD5 methylation of rpL40 links ribosomal output to gastric cancer.

Juhyung Park, Jibo Wu, Krzysztof J Szkop

|Jan 31, 2024
Cytoskeleton remodeling induced by SMYD2 methyltransferase drives breast cancer metastasis.

Alexandre G Casanova, Gael S Roth, Simone Hausmann

Pageof 4

Frequent Collaborators

6 joint publications

Pawel K Mazur

3 joint publications

Brian D Strahl

3 joint publications

Xiaoyin Lu

2 joint publications

Michael M Shen